Head-To-Head Review: Aclaris Therapeutics (NASDAQ:ACRS) and Nuvation Bio (NYSE:NUVB)

Aclaris Therapeutics (NASDAQ:ACRS) and Nuvation Bio (NYSE:NUVB) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, valuation, dividends, profitability, analyst recommendations and institutional ownership.

Earnings & Valuation

This table compares Aclaris Therapeutics and Nuvation Bio”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83 million	102.14	-$64.92 million	($0.58)	-9.86
Nuvation Bio	$62.90 million	34.17	-$204.63 million	($0.44)	-13.91

Aclaris Therapeutics has higher earnings, but lower revenue than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Aclaris Therapeutics has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, Nuvation Bio has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Aclaris Therapeutics and Nuvation Bio, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1	0	5	3	3.11
Nuvation Bio	1	2	10	0	2.69

Aclaris Therapeutics presently has a consensus price target of $11.33, indicating a potential upside of 98.14%. Nuvation Bio has a consensus price target of $13.00, indicating a potential upside of 112.38%. Given Nuvation Bio’s higher possible upside, analysts plainly believe Nuvation Bio is more favorable than Aclaris Therapeutics.

Institutional & Insider Ownership

98.3% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are owned by institutional investors. 4.8% of Aclaris Therapeutics shares are owned by insiders. Comparatively, 30.1% of Nuvation Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Aclaris Therapeutics and Nuvation Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-921.50%	-61.65%	-42.41%
Nuvation Bio	-88.18%	-46.59%	-22.01%

Summary

Nuvation Bio beats Aclaris Therapeutics on 9 of the 15 factors compared between the two stocks.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

About Nuvation Bio

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.